Kim Edmonds

1.7k total citations
16 papers, 560 citations indexed

About

Kim Edmonds is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kim Edmonds has authored 16 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kim Edmonds's work include Renal cell carcinoma treatment (5 papers), Cutaneous Melanoma Detection and Management (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Kim Edmonds is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Cutaneous Melanoma Detection and Management (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Kim Edmonds collaborates with scholars based in United Kingdom, Netherlands and France. Kim Edmonds's co-authors include Martin Gore, James Larkin, Julia Newton‐Bishop, Louise Fearfield, R. K. Sinha, Kate Hall, David Chao, Kellie A. Charles, Frances R. Balkwill and Tim Eisen and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Kim Edmonds

15 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kim Edmonds United Kingdom	9	317	222	120	84	75	16	560
Liwei Chen United States	15	239 0.8×	429 1.9×	140 1.2×	142 1.7×	121 1.6×	38	730
Yi Ling Teo Singapore	9	262 0.8×	228 1.0×	150 1.3×	130 1.5×	52 0.7×	11	625
Wendy Burke United Kingdom	12	318 1.0×	459 2.1×	74 0.6×	126 1.5×	78 1.0×	20	761
Christopher Toth United States	11	211 0.7×	229 1.0×	132 1.1×	54 0.6×	53 0.7×	15	586
Emman Shubbar Sweden	11	163 0.5×	297 1.3×	104 0.9×	108 1.3×	120 1.6×	25	608
Junko Baba Japan	5	216 0.7×	237 1.1×	70 0.6×	112 1.3×	84 1.1×	5	548
Vijay Shahani Canada	11	246 0.8×	369 1.7×	75 0.6×	64 0.8×	43 0.6×	19	711
Luisa Shin Ogawa United States	9	164 0.5×	452 2.0×	91 0.8×	99 1.2×	90 1.2×	17	679
Raewyn Poole Germany	13	224 0.7×	404 1.8×	110 0.9×	73 0.9×	54 0.7×	23	867

Countries citing papers authored by Kim Edmonds

Since Specialization

Citations

This map shows the geographic impact of Kim Edmonds's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Edmonds with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Edmonds more than expected).

Fields of papers citing papers by Kim Edmonds

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Edmonds. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Edmonds. The network helps show where Kim Edmonds may publish in the future.

Co-authorship network of co-authors of Kim Edmonds

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Edmonds. A scholar is included among the top collaborators of Kim Edmonds based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Edmonds. Kim Edmonds is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Nankivell, Matthew, Matteo Quartagno, Caroline S. Clarke, et al.. (2022). REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers. Contemporary Clinical Trials. 124. 107030–107030. 12 indexed citations

Fendler, Annika, Lewis Au, Fiona Byrne, et al.. (2021). 1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study. Annals of Oncology. 32. S1129–S1129. 10 indexed citations

Fendler, Annika, Lewis Au, Scott T.C. Shepherd, et al.. (2020). CAPTURE: Cancer and COVID-19 antiviral immune monitoring study. Clinical Cancer Research. 26(18).

O’Reilly, Aine, Jhia Jiat Teh, Emma McLean, et al.. (2019). An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Supportive Care in Cancer. 28(2). 561–570. 52 indexed citations

Grande, Enrique, Hilary Glen, Javier Aller, et al.. (2017). Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma. Expert Opinion on Drug Safety. 16(12). 1413–1426. 2 indexed citations

Seifert, Heike, Rosalie Fisher, Juan Martín-Liberal, et al.. (2015). Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib. Melanoma Research. 26(2). 138–144. 8 indexed citations

Edmonds, Kim, et al.. (2013). Erythema Nodosum–Like Panniculitis in Patients With Melanoma Treated With Vemurafenib. Journal of Clinical Oncology. 31(19). e320–e321. 19 indexed citations

Sinha, R. K., Kim Edmonds, Julia Newton‐Bishop, et al.. (2012). Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. British Journal of Dermatology. 167(5). 987–994. 83 indexed citations

Edmonds, Kim, et al.. (2012). Managing the side effects of vemurafenib therapy. Cancer Nursing Practice. 11(5). 14–21. 1 indexed citations

10.

Khattak, Muhammad A., Kim Edmonds, Komel Khabra, et al.. (2012). Interim Results of a Phase II Study of Sunitinib and Low Dose Metronomic Cyclophosphamide in Advanced Renal Cell Cancer. Annals of Oncology. 23. ix273–ix274. 1 indexed citations

11.

Edmonds, Kim, et al.. (2011). Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group. European Journal of Oncology Nursing. 16(2). 172–184. 34 indexed citations

12.

Larkin, James, Samra Turajlic, Paul Nathan, et al.. (2011). A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM).. Journal of Clinical Oncology. 29(15_suppl). TPS229–TPS229. 1 indexed citations

13.

Larkin, James, Tom Ferguson, Lisa Pickering, et al.. (2010). A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. British Journal of Cancer. 103(8). 1149–1153. 33 indexed citations

14.

Edmonds, Kim, et al.. (2010). Managing adverse events associated with sorafenib in renal cell carcinoma. British Journal of Nursing. 19(1). 58–60. 3 indexed citations

15.

Harrison, Michelle, Nick Maisey, Susan Hoare, et al.. (2007). Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose. Journal of Clinical Oncology. 25(29). 4542–4549. 195 indexed citations

16.

Marshall, M. Ernest, James L. Mohler, Kim Edmonds, et al.. (1994). An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin. Journal of Cancer Research and Clinical Oncology. 120(S1). S39–S42. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact